Proteinase-activated receptor 2 expression in breast cancer and its role in breast cancer cell migration

Proteinase-activated receptor 2 (PAR2) is a G protein-coupled receptor that is activated by trypsin-like proteinases. PAR2 is detected in breast tumor specimens; however, it is not clear how PAR2 level in breast cancer cell/tissues compares with normal cell/tissues. Here, we show the elevation of PAR2 protein level in 76 of 105 breast tumor specimens but only 5 of 24 normal breast tissues. PAR2 level is also higher in breast cancer cell lines than that in normal breast cells and non-cancerous breast cell lines. To determine the role of PAR2 in breast carcinogenesis, we examined the effect of PAR2 agonists on cell proliferation and migration. Our studies show that PAR2 agonists (PAR2-activating peptide and trypsin) are neither potent growth enhancers nor chemoattractants to breast cancer cells. Instead, PAR2 agonists induce significant chemokinesis. PAR2-mediated chemokinesis is Gαi-dependent, and inhibiting Src kinase activity or silencing c-Src expression blocks PAR2-mediated chemokinesis. These results suggest that c-Src works downstream of Gαi to mediate this PAR2 agonist-induced event. To characterize c-Src effector, we reveal that PAR2 agonists activate JNKs in a Src-dependent manner and that JNK activity is essential for PAR2-mediated chemokinesis. Moreover, PAR2 agonist stimulation leads to paxillin Ser178 phosphorylation and paxillin(S178A) mutant inhibits PAR2-mediated chemokinesis. In conclusion, our studies show that PAR2 agonists facilitate breast cancer cell chemokinesis through the Gαi-c-Src-JNK-paxillin signaling pathway.

[1]  L. Spagnoli,et al.  Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation. , 2006, The American journal of pathology.

[2]  Xin-Yun Huang,et al.  Src Tyrosine Kinase Is a Novel Direct Effector of G Proteins , 2000, Cell.

[3]  R. Raval,et al.  Identification of novel VHL targets that are associated with the development of renal cell carcinoma , 2007, Oncogene.

[4]  Shuji Mori,et al.  Physiology and pathophysiology of proteinase-activated receptors (PARs): PAR-2-mediated proliferation of colon cancer cell. , 2005, Journal of pharmacological sciences.

[5]  G. Johnson,et al.  Direct Interaction between Ras and the Kinase Domain of Mitogen-activated Protein Kinase Kinase Kinase (MEKK1) (*) , 1995, The Journal of Biological Chemistry.

[6]  W. Ruf,et al.  Role of Protease Activated Receptor 1 and 2 Signaling in Hypoxia-Induced Angiogenesis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[7]  C. Turner,et al.  Paxillin: adapting to change. , 2004, Physiological reviews.

[8]  W. Ruf,et al.  Thrombin generation and the pathogenesis of cancer. , 2006, Seminars in thrombosis and hemostasis.

[9]  H. Körner,et al.  Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis , 2006, The Journal of pathology.

[10]  P. Poučková,et al.  Proteinase-activated receptor-2 expression in breast cancer and the role of trypsin on growth and metabolism of breast cancer cell line MDA MB-231. , 2007, Physiological research.

[11]  A. Daneri-Navarro,et al.  Protease-activated receptor-2 (PAR-2) in cervical cancer proliferation. , 2008, Gynecologic oncology.

[12]  Ken Jacobson,et al.  JNK phosphorylates paxillin and regulates cell migration , 2003, Nature.

[13]  K. Hatakeyama,et al.  Tissue Factor Induces Migration of Cultured Aortic Smooth Muscle Cells , 1996, Thrombosis and Haemostasis.

[14]  Michael D Schaller,et al.  Paxillin: a focal adhesion-associated adaptor protein , 2001, Oncogene.

[15]  M. Hollenberg,et al.  Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein. , 2008, The Journal of biological chemistry.

[16]  J. Trejo,et al.  Protease-activated receptor-2 is essential for factor VIIa and Xa-induced signaling, migration, and invasion of breast cancer cells. , 2006, Cancer research.

[17]  M. Hollenberg,et al.  Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. , 2005, Human pathology.

[18]  M. Hollenberg,et al.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more , 2008, British journal of pharmacology.

[19]  T. Nishida,et al.  Role of JNK-dependent serine phosphorylation of paxillin in migration of corneal epithelial cells during wound closure. , 2008, Investigative ophthalmology & visual science.

[20]  S. Kitano,et al.  Protease‐activated receptor‐2 regulates cell proliferation and enhances cyclooxygenase‐2 mRNA expression in human pancreatic cancer cells , 2005, Journal of surgical oncology.

[21]  G. Johnson,et al.  MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42 , 1997, The EMBO journal.

[22]  M. Laburthe,et al.  Protease-activated Receptor 2 in Colon Cancer , 2004, Journal of Biological Chemistry.

[23]  B. M. Mueller,et al.  Protease-activated receptor-2 regulates vascular endothelial growth factor expression in MDA-MB-231 cells via MAPK pathways. , 2006, Biochemical and biophysical research communications.

[24]  M. Hollenberg,et al.  Proteinase-activated Receptor-2 Induces Cyclooxygenase-2 Expression through β-Catenin and Cyclic AMP-response Element-binding Protein* , 2008, Journal of Biological Chemistry.

[25]  J. Trejo.  Protease-Activated Receptors: New Concepts in Regulation of G Protein-Coupled Receptor Signaling and Trafficking , 2003, Journal of Pharmacology and Experimental Therapeutics.

[26]  J. Iovanna,et al.  Overexpression of p8 is inversely correlated with apoptosis in pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  J. Parsons,et al.  Src family kinases, key regulators of signal transduction , 2004, Oncogene.

[28]  M. Cobb,et al.  RhoA Binds to the Amino Terminus of MEKK1 and Regulates Its Kinase Activity* , 2004, Journal of Biological Chemistry.

[29]  Y. Kaziro,et al.  The Src family tyrosine kinase is involved in Rho-dependent activation of c-Jun N-terminal kinase by Gα12 , 1999, Oncogene.

[30]  H. Itoh,et al.  Src Kinase Regulates the Activation of a Novel FGD-1-related Cdc42 Guanine Nucleotide Exchange Factor in the Signaling Pathway from the Endothelin A Receptor to JNK* , 2003, Journal of Biological Chemistry.

[31]  R. Lefkowitz,et al.  Constitutive Protease-activated Receptor-2-mediated Migration of MDA MB-231 Breast Cancer Cells Requires Both β-Arrestin-1 and -2* , 2004, Journal of Biological Chemistry.

[32]  Da-Peng Yan,et al.  JNK regulates cell migration through promotion of tyrosine phosphorylation of paxillin. , 2008, Cellular signalling.

[33]  Dong-Yan Jin,et al.  P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. , 2007, Cancer research.

[34]  J. Parsons,et al.  pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk , 1995, Molecular and cellular biology.

[35]  Y. Takada,et al.  Hemostasis, Thrombosis, and Vascular Biology: Inhibition of tissue factor signaling suppresses tumor growth , 2014 .

[36]  M. Ciccarelli,et al.  Endothelial beta2 adrenergic signaling to AKT: role of Gi and SRC. , 2007, Cellular signalling.

[37]  K. Jacobson,et al.  A Role for JNK-Paxillin Signaling in Cell Migration , 2004, Cell cycle.

[38]  S. Hawthorne,et al.  Amplification of MMP‐2 and MMP‐9 production by prostate cancer cell lines via activation of protease‐activated receptors , 2004, The Prostate.

[39]  J. Trejo,et al.  Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer , 2007, Journal of Cell Science.

[40]  J. Iovanna,et al.  Expression of p8 in human pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  L. Brass,et al.  Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. , 2004, Molecular cancer research : MCR.

[42]  S. Frisch,et al.  The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration , 2006, Oncogene.

[43]  M. D'Andrea,et al.  Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. , 2001, The American journal of pathology.

[44]  H. Herschman,et al.  v-src Induces Prostaglandin Synthase 2 Gene Expression by Activation of the c-Jun N-terminal Kinase and the c-Jun Transcription Factor (*) , 1995, The Journal of Biological Chemistry.

[45]  G. Cottrell,et al.  Protease-activated receptor 2: activation, signalling and function. , 2003, Biochemical Society transactions.

[46]  G. Tsujimoto,et al.  Endothelin suppresses cell migration via the JNK signaling pathway in a manner dependent upon Src kinase, Rac1, and Cdc42 , 2002, FEBS letters.

[47]  U. Pendurthi,et al.  Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. , 2004, Blood.

[48]  R. Vessella,et al.  Overexpression of protease‐activated receptors‐1,‐2, and‐4 (PAR‐1, ‐2, and ‐4) in prostate cancer , 2007, The Prostate.